However, given GNBT’s history of over-promising (if only because of Joe’s boundless enthusiasm!) and under-delivering (sigh), it would make sense not to expect much on any of these fronts during this week’s call. And to count ourselves fortunate if even one of them shows solid progress.
So if you’re only going to get one, which would be most impactful on the pps? FDA/IND? China IND? NGIO IPO?
Generex Biotechnology Corp. (GNBT) Stock Research Links